1.                  Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998;25(1):139-51.

2.                  Finnegan LP. Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs 1991;23(2):191-201.

3.                  Fitzsimmons J, Tunis S, Webster D, Izes J, Wapner R, Finnegan L. Pregnancy in a drug-abusing population. Am J Drug Alcohol Abuse 1986;12(3):247-55.

4.                  Kaltenbach K, Finnegan LP. Perinatal and developmental outcome of infants exposed to methadone in-utero. NIDA Res Monogr 1987;76:276.

5.                  Finnegan LP. Management of pregnant drug-dependent women. Ann N Y Acad Sci 1978;311:135-46.

6.                  Hoegerman G. Narcotic Use in Pregnancy. Clinics in Perinatology 1991;18:51 - 76.

7.                  Kreek MJ. Analysis of methadone and other drugs in maternal and neonatal body fluids: use in evaluation of symptoms in a neonate of  mother maintained on methadone. American Journal Drug Alcohol Abuse 1974;1:409 - 19.

8.                  Wittmann M. A comparison of the effects of single- and split-dose methadone administration on the fetus: Ultrasound evaluation. International Journal of Addictions 1991;26:213-18.

9.                  Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. Journal of Pharmacology and Experimental Therapeutics 1985;233:1-6.

10.              Kreek MJ. Methadone disposition during the perinatal period in humans. Pharm Biochem Beh 1979;11:7-13.

11.              Wang EC. Methadone treatment during pregnancy. Journal of Obstetric, Gynecologic, & Neonatal Nursing 1999;28(6):615-22.

12.              Marquet P, Chevrel J, Lavignasse P, Merle L, Lachatre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 1997;62(5):569-71.

13.              Pani P, Maremmani I, Pirastu R, Tagliamonte A, Gessa G. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence 2000;60(Jul 1):39-50.

14.              Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999;94(Sep):1337-47.

15.              Williams A.When the client is pregnant: information for counselors. J Subst Abuse Treat 1985;2(1):27-34.

16.              Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. N.Y.: Exerpta Medica; 1986.

17.              Committee on Drugs AAoP. Neonatal Drug Withdrawal. Pediatrics 1998;101(No. 6):1079 - 88.

18.              McCarthy JJ, Posey BL. Methadone levels in human milk. J Human Lactation 2000;16(2):115-20.

19.              Silver H, Wapner R, Loriz-Vega M, Finnegan LP. Addiction in pregnancy: high risk intrapartum management and outcome. J Perinatol 1987;7(3):178-84.

20.              Mack G. Methadone levels and neonatal withdrawal. J. Pediatr Child Health 1991;27:96 - 100.

21.              Rosen TS. Disposition of methadone and its relationship to severity of withdrawal in the newborn. Addict. Dis. 1975;2:169 -78.

22.              Doberczak TM, Kandall SR, Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993;81(6):936-40.

23.              Rosen RS. Pharmacologic Observation on the neonatal withdrawal syndrome. J. Pediatrics 1976;89:1004 - 48.

24.              Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin. Pediatr. 1975;14:592 - 94.

25.              Ostrea EM. Infants of drug dependent-mothers. Philadelphia : WB Saunders; 1993.

26.              Martinez A, Kastner B, Taeusch HW. Hyperphagia in neonates withdrawing from methadone. Archives of Disease in Childhood Fetal & Neonatal Edition 1999;80(3).

27.              D'Apolito K. Comparison of a rocking bed and standard bed for decreasing withdrawal symptoms in drug-exposed infants. Journal of Maternal Child Nursing 1999:138-44.

28.              Finnegan LP, Mitros TF, Hopkins LE. Management of neonatal narcotic abstinence utilizing a phenobarbital loading dose method. NIDA Res Monogr 1979;27:247-53.

29.              Hoder EL, Leckman JF, Poulsen J, Caruso KA, Ehrenkranz RA, Kleber HD, et al. Clonidine treatment of neonatal narcotic abstinence syndrome. Psychiatry Res 1984;13(3):243-51.

30.              Malpas TJ, Darlow BA. Neonatal abstinence syndrome following abrupt cessation of breastfeeding. N Z Med J 1999;112(1080):12-3.

31.              Atkinson HC. Prediction of drug distribution intohuman milk from physiochemical characteristics. Clinical Pharmacokinetics 1990;18:151.

32.              Lawrence RA. Breastfeeding. fifth ed. St. Louis : Mosby; 1999.

33.              Geraghty B, Graham EA, Logan B, Weiss EL. Methadone levels in breast milk. J Hum Lact 1997;13(3):227-30.

34.              Blinick G, Inturriel CE, Jerez B, Wallace RC. Methadone assays in pregnant women and progeny. Am. J. Obstet.Gynecol. 1975;121:617-21.

35.     Jones H. Shorter dosing interval of opiate solution shortens hospital stay  for methadone babies. Family Medicine 1999;31(May):327-30.

About Dr. Ballard

Dr. Ballard is an associate professor of Pediatrics, Obstetrics and Gynecology at the University of Cincinnati College of Medicine. More ...